Piper Sandler Initiates RxSight(RXST.US) With Hold Rating, Announces Target Price $18
This Aurora Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday
Express News | Rxsight Inc : Piper Sandler Initiates Coverage With Neutral Rating; Price Target $18
Needham Maintains RxSight(RXST.US) With Buy Rating, Cuts Target Price to $22
UBS Downgrades RxSight(RXST.US) to Hold Rating, Cuts Target Price to $16
UBS Downgrades RxSight to Neutral From Buy, Cuts Price Target to $16 From $45
RxSight Is Maintained at Buy by Needham
RxSight's Market Challenges and Revised Growth Projections Lead to Hold Rating
Express News | Rxsight Inc : Needham Cuts Target Price to $22 From $43
RxSight Price Target Cut to $17.00/Share From $22.00 by Wells Fargo
RxSight Analyst Ratings
Wells Fargo Maintains RxSight(RXST.US) With Hold Rating, Cuts Target Price to $17
Analysts Are Neutral on Top Healthcare Stocks: RxSight (RXST), Johnson & Johnson (JNJ)
Top 10 Russell 2000 Weekly Gainers and Losers as Wall Street Crashes
When Should You Buy RxSight, Inc. (NASDAQ:RXST)?
SA Rating Changes: CHTR, RIVN, EE, WASH, DV, LZ, RXST
JP Morgan Downgrades RxSight on Market, Competitive Pressures
A Quick Look at Today's Ratings for RxSight(RXST.US), With a Forecast Between $22 to $43
Deep Dive Into RxSight Stock: Analyst Perspectives (12 Ratings)
JP Morgan Downgrades RxSight to Underweight, Lowers Price Target to $17